<DOC>
	<DOCNO>NCT01458028</DOCNO>
	<brief_summary>Single dose study BAY85-3934 compare placebo young/elderly male female healthy subject . The main focus study determine pharmacokinetics ( drug level blood ) BAY85-3934 similar four subject group . Qualifying subject dose single tablet BAY85-3934 ( placebo ) blood drawn 4 day . The safety tolerability BAY85-3934 compare placebo also evaluate 5 day study .</brief_summary>
	<brief_title>Age Gender Effects Pharmacokinetics BAY85-3934</brief_title>
	<detailed_description />
	<criteria>No diagnosis specific disease condition Subjects expect good general health respective age range Male female gender Age subgroup : 1 ) 18 45 year ( inclusive ) 2 ) 65 85 year ( inclusive ) Racial group : Caucasian Preexisting disease assume absorption , distribution , metabolism , elimination effect study drug normal . This include moderate severe renal impairment ( dialysis ) , moderate severe hepatic disease . Clinically relevant finding physical examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>BAY85-3934</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>age</keyword>
	<keyword>gender</keyword>
</DOC>